{"id":"W4291012346","doi":"10.1016/j.ejca.2022.06.041","title":"Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sandoz; Merck Sharp and Dohme; EMD Serono; Genentech; Qbiotics; Sun Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; BeiGene; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Amarin Corporation; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; Les Laboratories Pierre Fabre; Array BioPharma; AbbVie; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; American Society of Clinical Oncology; Bristol-Myers Squibb; Amgen; Hexal AG; Incyte; Pfizer; Gilead UK and Ireland Corporate Contributions; Castle Biosciences; Roche; Astellas Pharma US","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Cancer; Internal medicine; Hazard ratio; Oncology; Stage (stratigraphy); Adjuvant; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001960809,0.000636786,0.0009992151,0.0001788221,0.0002263852,0.0007585496,0.0004901065,0.0009115844,0.001789878],"category_scores_gemma":[0.001228598,0.0002354315,0.001268426,0.0001738139,0.0004262383,0.0005104958,0.000290629,0.001525708,0.0003704585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005519147,"about_ca_system_score_gemma":0.000641003,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005715706,"about_ca_topic_score_gemma":0.001275214,"domain_scores_codex":[0.999551,0.0002584124,0.00002477882,0.00007475416,0.00003618442,0.00005474841],"domain_scores_gemma":[0.9991505,0.0001973462,0.000299329,0.0001003241,0.00005760468,0.0001948659],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9213204,0.006126433,0.01834057,0.0006652251,0.001837661,0.00007473156,0.0001131813,0.001327517,0.007383778,0.0001025243,0.001837078,0.04087089],"study_design_scores_gemma":[0.5741209,0.3254386,0.08822977,0.0001594628,0.002612657,0.0003241715,0.00006239919,0.002524052,0.003019681,0.0003568955,0.003088687,0.00006268058],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964952,0.001953947,0.0001042398,0.0001234195,0.00006361185,0.000231057,0.0004031987,0.00001585819,0.000609533],"genre_scores_gemma":[0.9959928,0.0006529733,0.0003002891,0.0003381623,0.0001400761,0.0004406519,0.001084555,0.000006708939,0.001043697],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001960809,"threshold_uncertainty_score":0.0103699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02135862200431434,"score_gpt":0.3109600151685272,"score_spread":0.2896013931642129,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}